When people take nitroglycerin for a long time, the enzyme that activates it becomes less active, which reduces the production of nitric oxide and causes the drug to stop working as well.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether interventions that preserve mitochondrial aldehyde dehydrogenase activity (e.g., N-acetylcysteine) consistently prevent or reverse nitroglycerin tolerance across randomized trials.
A systematic review and meta-analysis of all randomized controlled trials testing agents that modulate mitochondrial aldehyde dehydrogenase (e.g., N-acetylcysteine, lipoic acid) on the incidence and severity of nitroglycerin tolerance in patients with angina, using standardized definitions of tolerance and outcome measures (e.g., dose escalation, hemodynamic response).
An RCT could determine whether preventing mitochondrial aldehyde dehydrogenase inhibition delays or prevents the onset of nitroglycerin tolerance in humans.
A double-blind RCT of 120 patients with stable angina receiving daily nitroglycerin patches for 14 days, randomized to receive either N-acetylcysteine (1200 mg/day) or placebo, with primary outcome being the change in mitochondrial aldehyde dehydrogenase activity in peripheral blood mononuclear cells and secondary outcomes including change in nitroglycerin efficacy (angina frequency, nitrate consumption).
A prospective cohort could determine whether the rate of decline in mitochondrial aldehyde dehydrogenase activity predicts the timing and severity of nitroglycerin tolerance development.
A prospective cohort of 150 patients initiating chronic nitroglycerin therapy, with mitochondrial aldehyde dehydrogenase activity measured weekly in leukocytes and clinical tolerance assessed by daily angina diary and nitrate dose requirements over 8 weeks.
A case-control study could compare mitochondrial aldehyde dehydrogenase activity levels in patients who developed tolerance versus those who maintained response after identical nitroglycerin exposure.
A case-control study comparing mitochondrial aldehyde dehydrogenase activity in leukocytes from 50 patients with documented nitroglycerin tolerance (dose doubled over 4 weeks) and 50 matched controls who maintained efficacy at baseline dose, matched for age, sex, comorbidities, and total nitroglycerin exposure.
A cross-sectional study could correlate the duration of nitroglycerin use with mitochondrial aldehyde dehydrogenase activity in a group of patients.
A cross-sectional study measuring mitochondrial aldehyde dehydrogenase activity in leukocytes of 200 patients on chronic nitroglycerin therapy, stratified by duration of use (<1 month, 1–3 months, >3 months), and correlating with self-reported efficacy and nitrate dose.